A potent and selective human α1D adrenoceptor (α1D-AR) antagonist with Ki of 1.1 nM.

A potent and selective human α1D adrenoceptor (α1D-AR) antagonist with Ki of 1.1 nM.

A potent and selective human PPARα agonist with EC50 of 4 nM, >1,000-fold selectivity over human PPARγ (EC50=4.5 uM) and PPARδ (EC50 >100 uM) in PPAR-GAL4 transactivation assays.

A potent and selective HDAC8 inhibitor with IC50 of 70 nM.

A potent and selective HDAC8 inhibitor with IC50 of 0.5 uM..

A potent and selective HDAC3 inhibitor with IC50 of 0.26 uM, with no activity against HDAC1/4/6/8.

A potent and selective HDAC3 inhibitor with IC50 of 0.24 uM, >75-fold selectivity over HDAC1 and no activity against HDAC4/6/8.

A potent and selective group I PAK (pan-PAK1/2/3) inhibitor with Ki of 0.95/2 nM for PAK1/2, respectively.

A potent and selective GlyT1 inhibitor with EC50 of 54 nM.

A potent and selective dopamine D3 receptor antagonist with pKi of 8.0.

A potent and selective Chk2 inhibitor with Ki/IC50 of 11 nM/120 nM.

A potent and selective ATP-competitive inhibitor of CHK2 K5777:N5777with IC50 of 3 nM.

A potent and selective antagonist of H3 receptor with Ki/EC50 of 0.16/1.5 nM.

A potent and selective antagonist of H3 receptor with Ki/EC50 of 0.16/1.5 nM.

A potent and selective ALK5 inhibitor with IC50 of 5.5 nM, displays 300-fold selecitvity over ALK3.

A potent and selective agonist for the cannabinoid receptor CB1 with Ki of 0.28 nM, 180-fold selectivity over CB2..

A potent and selective 5-HT3 receptor antagonist has been shown to be beneficial in the treatment of irritable bowel syndrome..

A potent and selective 5-HT2C receptor agonist with EC50 of 190 nM, with excellent selectivity for 5-HT2C over 5-HT2A.

A potent and selective 5-HT1A receptor antagonist.

A potent and selective (up to 263-fold) inhibitor of breast cancer cells with GI50 of 0.5 uM (MCF-7), via activation the aryl hydrocarbon receptor (AhR) pathway.

A potent and orally bioavailable dual antagonist of CCR2 and CCR5 with binding IC50 of 0.7 nM and 2.4 nM, respectively.

A potent and orally active p53-MDM2 interaction inhibitor with IC50 of 2.4 nM.

A potent and highly specific inhibitor of Aurora B and Aurora C with IC50 of 7 and 12 nM respectively, with less activity against Aurora A (IC50>2 uM).

A potent and highly selective D4 dopamine receptor antagonist with Ki of 3.5 nM, >200-fold selectivity over D2 and D3 receptors.

A potent and highly selective Chk2 inhibitor with IC50 of 0.14 nM.

A potent and effective calcium-sensitive opener of maxi-K potassium channels (maxi-K) with EC50 of 392 nM at -48.4 mV in HEK293 isolated outside-out membrane patches.

A potent and biologically-active PDE4/7 inhibitor with IC50 of 50-100 nM for PDE4A/B/D, and 140 nM for both PDE7A/B.

A potent and balanced dual PPARα/γ agonist (EC50= 50/21 nM).

A potent AHR (aryl hydrocarbon receptor) agonist that induces degradation of AhR by the ubiquitin-proteasome pathway.

A potent adenosine transport activity of ENT-1 with IC50 of 26.9 nM.